Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093954 | 0.85 | FOLH1 (0.53) | FPR2FOLH1 | |
| SCHEMBL28216420 | 0.83 | FOLH1 (0.61) | FPR2FOLH1 | |
| SCHEMBL9333451 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL18277722 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL9056129 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL11418240 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL9333446 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL6375756 | 0.81 | FPR2 (0.81) | FPR2FOLH1 | |
| SCHEMBL6381444 | 0.81 | FPR2 (0.81) | FPR2FOLH1 | |
| SCHEMBL6375751 | 0.81 | FPR2 (0.81) | FPR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051625-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | Du Pont Pharmaceuticals Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |